Core Viewpoint - Huajian Medical (01931) has seen a stock increase of over 11%, currently at 1.78 HKD, with a trading volume of 20.59 million HKD, following the announcement of a dual-platform testing solution for Nipah virus developed by its subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd [1] Group 1 - The dual-platform testing solution includes a smart fluorescence PCR rapid detection platform and a high-throughput sequencing and intelligent analysis platform, providing comprehensive technical support from rapid screening to precise tracing [1] - The rapid implementation of Nipah virus testing capabilities showcases the technological strength of Carbon Hua Biotechnology and represents a significant step in Huajian Medical's overall AI healthcare strategy [1] - The company is accelerating the establishment of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang Technology Co., Ltd (300451.SZ) [1]
华检医疗涨超11% 子公司成功研发尼帕病毒双平台检测解决方案